NCT01719744

Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma

A Phase II Study of Oral ENMD-2076 Administered to Patients With Advanced/Metastatic Soft Tissue Sarcoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 study of ENMD-2076 in patients with advanced/metastatic soft tissue sarcoma. This study will help to understand how well ENMD-2076 works and how safe and tolerable the drug is in this patient population.

Detailed description

ENMD-2076 is an oral drug that works by blocking certain enzymes called Aurora A from working. These enzymes are needed for cells to divide including cancer cells. ENMD-2076 also works by stopping the growth of new blood vessels which would provide the tumor with nutrients for it to grow. It is believed that by blocking Aurora A enzymes from working and stopping new blood vessels from growing, the tumors may stop growing or shrink.

Conditions

• Advanced
• Metastatic
• Soft Tissue Sarcoma

Interventions

Type	Name	Description
DRUG	ENMD-2076

Timeline

• Start date: 2013-01-01
• Primary completion: 2015-12-01
• Completion: 2016-01-01
• First posted: 2012-11-01
• Last updated: 2023-08-01
• Results posted: 2017-11-07

Locations

1 site across 1 country: Canada